Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | PPARA | Q07869 | 3/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7972410 | 0.91 | MAPT (0.71) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14675979 | 0.88 | MAPT (0.67) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4678107 | 0.86 | MAPT (0.69) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14676830 | 0.84 | MAPT (0.71) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL27896444 | 0.83 | MAPT (0.70) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14675442 | 0.82 | MAPT (0.67) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5948746 | 0.82 | ALOX5 (0.65) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL6902202 | 0.81 | MAPT (0.66) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL6689290 | 0.81 | PDK1 (0.69) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14675893 | 0.81 | MAPT (0.63) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409904-B2 | Compounds and compositions for use in augmentation of glucose | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-08-09 | — | — | US | disclosed |
| US-20150025094-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-01-22 | — | — | US | disclosed |
| EP-2739612-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE UPTAKE AND INSULIN SECRETION | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013018095-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE UPTAKE AND INSULIN SECRETION | YISSUM RESEARCH AND DEVELOPMENT OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-02-07 | — | — | WO | disclosed |
| US-7691841-B2 | Azetidine derivatives as CCR-3 receptor antagonist | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| EP-1781606-B1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20070259848-A1 | Azetidine Derivatives as Ccr-e Receptor | NOVARTIS AG (CH) | 2007-11-08 | — | — | US | disclosed |
| EP-1781606-A2 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006015854-A2 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025094-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE | SLC5A2, SLC2A2, SLC2A1 | MAPT 4597/4885LMNA 1819/4885HPGD 1718/4885 |
| US-20070259848-A1 | Azetidine Derivatives as Ccr-e Receptor | CCR1, CCR3, CCR9 | MAPT 3413/4885LMNA 3959/4885HPGD 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.